Micro-Costing Analysis of Adverse Events of Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Therapy in the United States (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-294; Location: LEVEL 3, HALL B3; "Inotuzumab and blinatumomab were driven by infections (fungal, $17537 vs $1754; bacterial, $4608 vs $11729). This analysis provides the first comprehensive ingredient-level costing of AEs for pediatric R/R BALL, capturing costs from routine management to ICU care. The findings identify major cost drivers, quantify toxicity burden, and offer a reproducible framework to inform clinical and reimbursement decisions. aGVHD: acute graft-vs-host disease, CAR-HLH: hemophagocytic lymphohistiocytosis associated with CAR-T therapy, CAR-T: chimeric antigen receptor T-cell, cGVHD: chronic graft-vs-host disease, CRS: cytokine release syndrome, HSCT: hematopoietic stem cell transplantation, ICANS: immune effector cell–associated neurotoxicity syndrome."
Adverse events • Clinical • HEOR • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Marleni Torres Nunez MD 1; Aleksandra Oszer MD 2; Rocio Caja Rivera PhD 1; Hannah Sauer PharmD 1; Jennifer McArthur MD 1; Hope Swanson PharmD 1; Patricia Barker PharmD 1; Frank Fazio MS 1; Timothy Lockey PhD 1; Caitlyn Duffy MD PhD 1; Nickhill Bhakta MD 1; Seth Karol MD 1; Aimee Talleur MD 1; Nancy Bolous MD 1
|